SCHEMBL2946233

SCHEMBL2946233

C=Cn1cc(C2=C(c3ccccc3OCC(O)CN(C)C)C(=O)NC2=O)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 4/20 0.51
PRKCB P05771 3/20 0.51
GSK3B P49841 3/20 0.51
PRKCG P05129 2/20 0.51
PRKACA P17612 3/20 0.42
PRKACG P22612 3/20 0.42
PRKACB P22694 3/20 0.42
CCNE2 O96020 2/20 0.41
CDK4 P11802 2/20 0.41
CCND1 P24385 2/20 0.41
CCNE1 P24864 2/20 0.41
CDK2 P24941 2/20 0.41
PRKCH P24723 2/20 0.40
PRKCD Q05655 2/20 0.40
PRKCQ Q04759 1/20 0.40
CCNB2 O95067 2/20 0.40
CDK1 P06493 2/20 0.40
CCNB1 P14635 2/20 0.40
CCNB3 Q8WWL7 2/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680124 0.88 PRKCA (0.47) PRKCAPRKCBGSK3BPRKCGPRKACA
SCHEMBL4676750 0.88 GSK3B (0.50) PRKCAPRKCBGSK3BPRKCGPRKACA
SCHEMBL4679997 0.85 GSK3B (0.51) PRKCAPRKCBGSK3BPRKCGPRKCH
SCHEMBL4683218 0.84 GSK3B (0.55) PRKCAPRKCBGSK3BPRKACAPRKACG
SCHEMBL4683103 0.82 PRKCA (0.64) PRKCAPRKCBGSK3BPRKCGPRKACA
SCHEMBL5756702 0.79 GSK3B (0.71) PRKCAPRKCBGSK3BPRKCGPRKACA
SCHEMBL13166876 0.77 ABCB1 (0.35) HTR1A
SCHEMBL7522437 0.76 CCNE2 (0.67) PRKCAGSK3BCCNE2CDK4CCND1
SCHEMBL3775971 0.74 GSK3B (0.61) PRKCAPRKCBGSK3BPRKCGPRKACA
SCHEMBL4684125 0.70 PRKCA (0.62) PRKCAPRKCBGSK3BPRKCGPRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS ZHANG HAN-CHENG 2010-09-23 US disclosed
US-7759380-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2010-07-20 US disclosed
US-7608634-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-10-27 US disclosed
EP-1513520-B1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors ZHANG HAN-CHENG 2007-09-13 US disclosed
US-20070213386-A1 Substituted pyrrolines as kinase inhibitors ZHANG HAN-CHENG 2007-09-13 US disclosed
US-7232906-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BG) 2007-06-19 US disclosed
US-20040054180-A1 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS PRKDC, MAP2K2, TTK PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885
US-20040054180-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885
US-20070213386-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK PRKCA 59/4885PRKCB 55/4885GSK3B 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.